AIM: We examined whether visual interpretation of relative cerebral blood volume (rCBV) color maps made with dynamic susceptibility-weighted perfusion MRI can reliably distinguish progressive disease (PD) from pseudoprogression (PsPD) in glioblastoma patients during treatment with temozolomide chemoradiation. MATERIALS & METHODS: Magnetic resonance (MR) perfusion-weighted images were evaluated based on visual inspection of rCBV maps. Sensitivity and specificity were calculated to assess if rCBV can reliably differentiate between PD and PsPD, during standard chemoradiation therapy. RESULTS: Evaluation of dynamic susceptibility-weighted contrast-enhanced perfusion MRI by visual interpretation of rCBV maps did not differentiate PD from PsPD (sensitivity = 72%; specificity = 23%). Furthermore, the interpretation of the rCBV maps had no prognostic value regarding survival. CONCLUSION: Qualitative rCBV-based dynamic susceptibility-weighted contrast-enhanced perfusion MRI does not reliably differentiate PD from PsPD, and is not prognostic for survival in glioblastoma multiforme patients during treatment with temozolomide chemoradiation.
AIM: We examined whether visual interpretation of relative cerebral blood volume (rCBV) color maps made with dynamic susceptibility-weighted perfusion MRI can reliably distinguish progressive disease (PD) from pseudoprogression (PsPD) in glioblastomapatients during treatment with temozolomide chemoradiation. MATERIALS & METHODS: Magnetic resonance (MR) perfusion-weighted images were evaluated based on visual inspection of rCBV maps. Sensitivity and specificity were calculated to assess if rCBV can reliably differentiate between PD and PsPD, during standard chemoradiation therapy. RESULTS: Evaluation of dynamic susceptibility-weighted contrast-enhanced perfusion MRI by visual interpretation of rCBV maps did not differentiate PD from PsPD (sensitivity = 72%; specificity = 23%). Furthermore, the interpretation of the rCBV maps had no prognostic value regarding survival. CONCLUSION: Qualitative rCBV-based dynamic susceptibility-weighted contrast-enhanced perfusion MRI does not reliably differentiate PD from PsPD, and is not prognostic for survival in glioblastoma multiformepatients during treatment with temozolomide chemoradiation.
Authors: Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan Journal: J Neurooncol Date: 2006-08-31 Impact factor: 4.130
Authors: Meng Law; Sarah Oh; James S Babb; Edwin Wang; Matilde Inglese; David Zagzag; Edmond A Knopp; Glyn Johnson Journal: Radiology Date: 2006-01-05 Impact factor: 11.105
Authors: L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman Journal: AJNR Am J Neuroradiol Date: 2008-12-04 Impact factor: 3.825
Authors: Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: E T Wong; E F Jackson; K R Hess; D F Schomer; J D Hazle; A P Kyritsis; K A Jaeckle; W K Yung; V A Levin; N E Leeds Journal: Neurology Date: 1998-03 Impact factor: 9.910
Authors: Joonmi Oh; Roland G Henry; Andrea Pirzkall; Ying Lu; Xiaojuan Li; Isabelle Catalaa; Susan Chang; William P Dillon; Sarah J Nelson Journal: J Magn Reson Imaging Date: 2004-05 Impact factor: 4.813
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi Journal: AJR Am J Roentgenol Date: 1998-12 Impact factor: 3.959
Authors: H R Arvinda; C Kesavadas; P S Sarma; B Thomas; V V Radhakrishnan; A K Gupta; T R Kapilamoorthy; S Nair Journal: J Neurooncol Date: 2009-02-20 Impact factor: 4.130